The desire of generics companies to diversify into the biologics arena has been demonstrated in the recent US$400 M acquisition of CoGenesys by the Israeli generics giant, Teva Pharmaceutical Industries. The appeal of Maryland-based CoGenesys is the company#8217;s proprietary platform technology, albumin fusion, which uses recombinant DNA technology to create proteins/peptides that have been modified to have reduced dosing, thus potentially increasing their safety. Teva is also gaining a reasonably populated pipeline of proteins targeting a range of different therapeutic categories.